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ABSTRACT 
Background: Tuberculosis is still an important problem in developing countries. The tuberculin skin test (TST) is used for the 
identification of latent tuberculosis (TB) infection. This study aimed to evaluate the TST results of healthy employees of 
different departments in chaharmahal province, Iran. 
Materials and Methods: This study was done on 1,424 healthy employees from 49 different departments in Chaharmahal 
Province. The tuberculin skin test was done with Purified Protein Derivative (PPD) solution. The induration was evaluated 48-
72 hours later. 
Results: Negative PPD test was observed in 346 subjects. A 5-10 mm induration was seen in 276, a 10-15 mm in 292, a 15-
20 mm in 212, a 20-25 mm in 72, and a 25-30 mm induration was observed in 14 cases. A total of 212 subjects were absent 
when reading the induration. 
Conclusion: Tuberculin skin test can be used for the identification of TB infection. Prevalence of latent TB infection was low 
in our study. There were no significant differences in PPD test results between medical and non-medical departments. 
(Tanaffos2011; 10(1): 37-39) 




Tuberculosis is one of the oldest diseases known 
to affect humans and is caused by bacteria belonging 
to the Mycobacterium tuberculosis complex. The 
disease usually affects the lungs, although in up to 
one-third of cases other organs are involved as well 
(1).Tuberculosis is still an important health hazard in 
developing countries (2).  
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The tuberculin skin test (TST) is used for the 
identification of latent tuberculosis (TB) infection 
(3). The purpose of this study was to evaluate the 
results of TST among employees of different 
departments in chaharmahal province, Iran.  
 
MATERIALS AND METHODS 
This study was conducted on 1,424 healthy 
employees from 49 medical and non-medical 
departments in Chaharmahal Province. After 
explaining the procedure to the subjects, tuberculin 
skin test (TST) was done on the anterior aspect of the 
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left forearm by injecting 0.1 ml of standard PPD 
solution with insulin syringe. The induration site was 
read 48-72 hours after injection. While reading the 




Negative PPD test was observed in 346 subjects. 
A 5-10 mm induration was observed in 276 cases, a 
10-15 mm induration in 292, a 15-20 mm induration 
in 212, a 20-25 mm induration in 72, and an 
induration equal to 25-30 mm was observed in 14 
cases. All participants with PPD result>15 were 
evaluated with CXR, CBC and ESR. No abnormality 
was detected in CBC, ESR or CXR of evaluated 
subjects. Table 1 summarizes the obtained results. 
 
Table 1. Frequency distribution of PPD test results 
 
PPD Number of cases (percent) 
<5mm 346 (28.5) 
5-10 mm 276 (22.8) 
10-15 mm 292 (24.1) 
15-20 mm 212 (17.5) 
20-25 mm 72 (5.9) 
25-30 mm 14 (1.2) 
 
There were no significant differences in PPD test 




In 1891, Robert Koch discovered components of 
M. tuberculosis in a concentrated liquid culture 
medium. Subsequently named "old tuberculin" (OT), 
this material was initially believed to be useful in the 
treatment of tuberculosis (although this idea was later 
disproved). It soon became clear that OT was capable 
of eliciting a skin reaction when injected 
subcutaneously into patients with tuberculosis. In 
1932, Seibert and Munday purified this product by 
ammonium sulfate precipitation. The result was an 
active protein fraction known as tuberculin PPD. 
However, the complexity and diversity of the 
constituents of PPD rendered its standardization 
difficult. PPD-S, developed by Seibert and Glenn in 
1941, was chosen as the international standard. Later, 
the WHO and UNICEF sponsored large-scale 
production of a master batch of PPD, termed RT23, 
and made it available for general use. The greatest 
limitation of PPD is its lack of mycobacterial species 
specificity, a property that is due to the large number 
of proteins in this product that are highly conserved 
in the various species of mycobacteria. Skin testing 
with PPD is most widely used in screening for M. 
tuberculosis infection. The test is of limited value in 
the diagnosis of active tuberculosis because of its low 
sensitivity and specificity (1). The tuberculin skin 
test (TST) is used for the identification of latent TB 
infection but lacks specificity in Mycobacterium 
bovis BCG-vaccinated individuals, who constitute an 
increasing proportion of TB patients and their 
contacts from regions where TB is endemic (3). The 
specificity of the tuberculin skin test for the diagnosis 
of latent tuberculosis infection is adversely affected 
by BCG vaccination and infection with non-
tuberculous mycobacteria (4). The tuberculin skin 
test used to detect latent Mycobacterium tuberculosis 
infection has many drawbacks, and a new diagnostic 
test for latent tuberculosis (QuantiFERON-TB) has 
been introduced (5).  This new diagnostic test 
measures the production of interferon (IFN)-gamma 
in whole blood upon stimulation with specific ESAT-
6 and CFP-10 antigens of Mycobacterium 
tuberculosis. Since most of the mycobacteria other 
than tuberculosis and BCG strain do not contain 
these antigens, the detection of IFN-gamma levels 
indicates the specific T-cell response against M. 
tuberculosis (6). Although IFN-gamma blood assay 
has many advantages such as objective and 
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quantitative results, no interference with vaccination 
due to the use of specific antigens and being 
practical, the high cost and the need for well-
equipped laboratories are among its disadvantages 
(6). Kang YA and Lee HW showed that IFN-gamma 
assay is a better indicator for evaluation of the risk of 
M. tuberculosis infection than TST in a BCG-
vaccinated population (7). IFN-gamma assay is less 
affected by BCG vaccination than TST for diagnosis 
of latent tuberculosis (8). Porsa et al. and Cheng et al. 
showed that reactivity of the IFN-gamma assay is 
unaffected by prior BCG vaccination or serial TSTs 
(9). Biological tests that measure the in-vitro 
production of interferon gamma will replace or 
complement TST in the diagnosis of latent 
tuberculosis in the near future (10). 
 
REFERENCES 
1. Raviglione MC, O'Brien RJ. Tuberculosis in: Kasper DL, 
Braunwald E, et al. Harrison’s principles of internal 
medicine16th ed. McGraw-Hill; 2005. P.953-965 
2. Yorulmaz F, Cağlar T, Erel C, Ozaydin M. Prevalence and 
annual risk of tuberculosis infection in Edirne, Turkey. 
Scand J Infect Dis 2002; 34 (9): 654- 6. 
3. Arend SM, Engelhard AC, Groot G, de Boer K, Andersen P, 
Ottenhoff TH, et al. Tuberculin skin testing compared with 
T-cell responses to Mycobacterium tuberculosis-specific and 
nonspecific antigens for detection of latent infection in 
persons with recent tuberculosis contact. Clin Diagn Lab 
Immunol 2001; 8 (6): 1089- 96. 
4. Tsiouris SJ, Austin J, Toro P, Coetzee D, Weyer K, Stein Z, 
et al. Results of a tuberculosis-specific IFN-gamma assay in 
children at high risk for tuberculosis infection. Int J Tuberc 
Lung Dis 2006; 10 (8): 939- 41. 
5. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. 
Comparison of tuberculin skin test and new specific blood 
test in tuberculosis contacts. Am J Respir Crit Care Med 
2004; 170 (1): 65- 9.  
6. Oztürk N, Sürücüoğlu S, Ozkütük N, Gazi H, Akçali S, 
Köroğlu G, et al. Comparison of interferon-gamma whole 
blood assay with tuberculin skin test for the diagnosis of 
tuberculosis infection in tuberculosis contacts. Mikrobiyol 
Bul 2007; 41 (2): 193- 202.  
7. Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, et 
al. Discrepancy between the tuberculin skin test and the 
whole-blood interferon gamma assay for the diagnosis of 
latent tuberculosis infection in an intermediate tuberculosis-
burden country. JAMA 2005; 293 (22): 2756- 61. 
8. Mazurek GH, LoBue PA, Daley CL, Bernardo J, Lardizabal 
AA, et al. Comparison of a whole-blood interferon gamma 
assay with tuberculin skin testing for detecting latent 
Mycobacterium tuberculosis infection. JAMA 2001; 286 
(14): 1740- 7. 
9. Porsa E, Cheng L, Seale MM, Delclos GL, Ma X, Reich R, et 
al. Comparison of a new ESAT-6/CFP-10 peptide-based 
gamma interferon assay and a tuberculin skin test for 
tuberculosis screening in a moderate-risk population. Clin 
Vaccine Immunol 2006; 13 (1): 53- 8. 
10. Lagrange PH, Simonney N, Herrmann JL. New 
immunological tests in the diagnosis of tuberculosis. Rev 
Mal Respir 2007; 24 (4 Pt 1): 453- 72. 
